Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cationic nanocarriers as potent adjuvants for recombinant S-RBD vaccine of SARS-CoV-2

11 Dec 2020

Abstract excerpt

The worldwide outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has urged the investigation of preventive vaccines. Recently, our team has developed a recombinant protein vaccine, targeting receptor binding domain (RBD) of the spike protein (S-RBD) of SARS-CoV-2, which could induce a potent antibody response and protect non-human primates from SARS-CoV-2 challenge. 1 The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immunotherapy and Immune Responses
Share to RNA Interference and Gene Delivery
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33311439
DOI: 10.1038/s41392-020-00434-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cationic nanocarriers as potent adjuvants for recombinant S-RBD vaccine of SARS-CoV-2PMID 33311439Read ↗

Next‐Generation Vaccines: Nanovaccines in the Fight against SARS‐CoV‐2 Virus and beyond SARS‐CoV‐2Semantic proximity Read ↗

Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 VariantsSemantic proximity Read ↗

Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2Semantic proximity Read ↗

Preclinical Study of DNA Vaccines Targeting SARS-CoV-2Semantic proximity Read ↗

Next generation vaccine platform: polymersomes as stable nanocarriers for a highly immunogenic and durable SARS-CoV-2 spike protein subunit vaccineSemantic proximity Read ↗

CoVac501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunitySemantic proximity Read ↗

SARS‐CoV‐2 Spike Stem Protein Nanoparticles Elicited Broad ADCC and Robust Neutralization against Variants in MiceSemantic proximity Read ↗

Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19Semantic proximity Read ↗

Safety and Immunogenicity of Nanocovax, a SARS-CoV-2 Recombinant Spike Protein VaccineSemantic proximity Read ↗

Receptor-binding domain as a target for developing SARS vaccines.Semantic proximity Read ↗

A Multivalent Vaccine Based on Ferritin Nanocage Elicits Potent Protective Immune Responses against SARS-CoV-2 Mutations.Semantic proximity Read ↗

DNA origami presenting the receptor binding domain of SARS-CoV-2 elicit robust protective immune responseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.